At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
MSDC-0160 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2A, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of Mitoglitazone™ in Type 2 Diabetic Patients
In Brief
A Phase 2 clinical trial evaluating Placebo, Pioglitazone, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 86 participants across 8 sites.
Detailed Summary
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionJan 2009
Study CompletionFeb 2009
TodayJul 2026
First PostedSep 26, 2008
Enrollment StartSep 1, 2008
Primary CompletionJan 1, 2009
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.8 years ago
Interventions
Placebodrug
Once daily, oral
Pioglitazonedrug
Once daily, oral
MSDC-0160 90 mgdrug
Once daily, oral
MSDC-0160 220 mgdrug
Once daily, oral